Meditation can better the brain. Are we morally obligated to meditate? – Vox.com

Eight weeks ago, I started meditating every day.

I knew Id be going home to visit my family at the end of December, and well, I have a bad habit of regressing into a 13-year-old whenever Im around them. All my old immaturities and anxieties get activated. I become a more reactive, less compassionate version of myself.

But this holiday season, I was determined to avoid fighting with my family. I would be kind and even-tempered throughout the visit. I knew that in order to have a chance in hell of achieving this, Id need a secret weapon.

Thats where the meditation came in.

Starting in 2005, Harvard neuroscientist Sara Lazar began to publish some mind-blowing findings: Meditation can literally change the structure of your brain, thickening key areas of the cortex that help you control your attention and emotions. Your brain and possibly, by extension, your behavior can reap the benefits if you practice meditation for half an hour a day over eight weeks.

Just eight weeks? I thought when I read the research. This seems too good to be true!

I was intrigued, if skeptical. Above all, I was curious to know more. And I wasnt the only one. By 2014, there had been enough follow-up studies to warrant a meta-analysis, which showed that meditators brains tend to be enlarged in a bunch of regions, including the insula (involved in emotional self-awareness), parts of the cingulate cortex and orbitofrontal cortex (involved in self-regulation), and parts of the prefrontal cortex (involved in attention).

A host of other studies showed that meditation can also change your neural circuitry in ways that make you more compassionate, as well as more inclined to have positive feelings toward a victim of suffering and to see things from their perspective.

Further research suggested that meditation can change not only your internal emotional states but also your actual behavior. One study found that people made charitable donations at a higher rate after being trained in meditation for just two weeks. Another study found that people who get that same measly amount of meditation training are about three times more likely than non-meditators to give up their chair when they see someone on crutches and in pain.

Still skeptical, I fell down an internet rabbit hole and soon found many more neuroscientific studies. Looking closely at them, I did find that a fair number are methodologically flawed (more on that below). But there were many others that seemed sound. Taken together, the literature on meditation suggested that the practice can help us get better at relating to one another. It confronted me with evidence that a few weeks of meditation can improve me as a person.

I say confronted because the evidence really did feel like a challenge, even a dare. If it takes such a small amount of time and effort to get better at regulating my emotions, paying attention to other people, seeing things from their point of view, and acting altruistically, then well am I not morally obligated to do it?

The word meditation actually refers to many different practices. In the West, the most well-known set of practices is mindfulness meditation. When people talk about that, theyre typically thinking of a practice for training our attention.

Heres how Jon Kabat-Zinn, a scientist who helped popularize mindfulness in the West, defines it: Mindfulness is awareness that arises through paying attention, on purpose, in the present moment, non-judgmentally.

And heres what mindfulness meditation practice often involves: You sit down, close your eyes, and focus on feeling your breath go in and out. When you feel your attention drifting to the thoughts that inevitably arise, you notice, and then gently bring your attention back to your breath.

This combination of attention training and direct observation is the basic practice. Sounds simple, right? But according to some studies, it can have profound effects on your brain.

In a 2012 study, people who were new to meditation underwent eight weeks of mindful attention training, practicing for around four hours each week. Before the training, they got fMRIs, scans that show where brain activity is occurring. While they were in the MRI scanner, they viewed a series of pictures, some of which were upsetting (like a photo of a burn victim). After eight weeks of mindfulness meditation, when they viewed the upsetting pictures in the scanner again, they showed reduced activity in a crucial brain region: the amygdala.

The amygdala is our brains threat detector. It scans our environment for danger, and when it perceives a threat, it sets off our fight-flight-freeze response, which includes releasing stress hormones like cortisol and adrenaline. It glues our attention to the threat, making it hard for us to focus on anything else.

Whats striking about the study is that the reduced amygdala activity lasted even when the participants were in their ordinary baseline state in other words, not actively practicing mindfulness. This suggests the effects of meditation may result in enduring changes in mental function, as the authors wrote. A control group showed no such effects.

In another, similarly designed study, participants showed reduced amygdala activity in response to upsetting pictures after practicing mindfulness for 20 minutes per day over just one week. However, the lessened amygdala reactivity only showed while they were engaged in mindfulness, suggesting we need more continued practice if we want the changes to be permanent.

To see why attention-training can be helpful when it comes to treating others better, think back to a time when you saw someone in distress. Maybe it was a friend who wanted to talk about his painful breakup, or a colleague who was caught in a swirl of anxiety, or a homeless person who needed something to eat.

If you were distracted by your own distressing thoughts if your amygdala was activating like crazy you may have had a hard time putting your issues aside long enough to deal with theirs. You may not have even noticed that they needed something from you until it was too late.

But if your mind is undisturbed, youll probably have an easier time paying attention to what the present moment asks of you: to help this person whos in front of you, right here, right now.

Thats common sense, said Thupten Jinpa, a Tibetan Buddhist scholar and the main English translator to the Dalai Lama. I grew up as a monk, so for me, the most powerful evidence is really the anecdotal evidence in my own personal life.

But as an academic with a PhD in religion, Jinpa doesnt rely only on common sense or personal experience he also works with psychologists on scientific research. In 2015, he co-authored a study titled A wandering mind is a less caring mind, which found that reducing mind-wandering through meditation was associated with increased caring behavior, both for oneself and for others.

Although Jinpa believes mindfulness is important, he told me that when it comes to making us more altruistic, theres another type of practice thats even more effective: loving-kindness or compassion meditation.

Two other meditation practices loving-kindness meditation and its close cousin, compassion meditation have interesting science behind them, too. These practices, which involve concentrated attention to cultivate certain qualities, have been growing in popularity in the West over the past couple of decades thanks to American teachers like Sharon Salzberg. And evidence shows they can change your neural circuitry even faster than mindfulness meditation.

The meditation for loving-kindness typically looks like this: You repeat certain phrases in your head, such as may I be safe, may I be healthy, or may my life unfold with ease. After youve wished these things for yourself, you widen the circle of caring, wishing the same things for the people you love, then for people you feel neutrally about, and then for all living beings including those who get on your nerves or have hurt you. (One compassion meditation works much the same way, except instead of wishing that people be safe and healthy and full of ease, you wish that they be free from suffering.)

So, how does loving-kindness or compassion meditation affect the brain, and in turn, affect our behavior?

Before we answer that question, its important to note that loving-kindness and compassion meditation which involve cultivating love for people who are suffering are not the same thing as empathy, even though we often conflate these concepts.

Empathy is when you share the feelings of other people. If other people are feeling pain, you feel pain, too literally.

Not so with compassion. In a 2013 study at the Max Planck Institute in Leipzig, Germany, researchers put volunteers in a brain scanner, showed them gruesome videos of people suffering, and asked them to empathize with the sufferers. The fMRI showed activated neural circuits centered around the insula exactly the circuits that get activated when were in pain ourselves.

Compare that with what happened when the researchers took a different group of volunteers and gave them eight hours of training in compassion, then showed them the graphic videos. A totally different set of brain circuits lit up: those for love and warmth, the sort a parent feels for a child.

When we feel empathy, we feel like were suffering, and thats upsetting. In the short term, it can cause us to tune out to help alleviate our own feelings of distress. And in the long term, it can cause serious burnout, as many a nurse and social worker can attest.

A little bit of empathy is important, because we need to be able to detect another persons suffering in order to be helpful, Richard Davidson, a prominent University of Wisconsin-Madison neuroscientist whos spent decades studying meditation in the lab, told me. But empathy by itself can be toxic.

Amazingly, compassion because it fosters positive feelings actually attenuates the empathetic distress that can cause burnout, as neuroscientist Tania Singer has demonstrated in her lab.

In other words, practicing compassion or loving-kindness doesnt just help us make other people happier; it makes us happier, too.

Loving-kindness also boosts the connections between the brains circuits for joy and happiness and the prefrontal cortex, a zone critical for guiding behavior, Davidson writes in Altered Traits, his authoritative 2017 book on the neuroscience of meditation, which he co-authored with Daniel Goleman. And the greater the increase in the connection between these regions, the more altruistic a person becomes following compassion meditation training.

In fact, one fMRI study showed that in very experienced practitioners (think Tibetan yogis), compassion meditation actually triggers activity in the brains motor centers, preparing their bodies to physically move in order to help whoever is suffering, even as theyre still lying in the brain scanner.

Given such evidence, Jinpa believes its clear that we can strengthen our compassion through concrete practices, just as we strengthen our muscles through exercise. Working out of Stanford Universitys Center for Compassion and Altruism Research and Education in 2009, he created the Compassion Cultivation Training, an eight-week course designed with input from neuroscientists and psychologists. Blending formal meditation with other contemplative practices, the course is now taught around the world.

After I started wondering if were morally obligated to meditate, I soon realized thats a very Western and Judeo-Christian way of thinking about it. Growing up, Id had to memorize the Ten Commandments and a long litany of sins, and my mind is still conditioned to think in terms of commandments and obligations.

But Eastern traditions like Buddhism or Confucianism arent grounded in commandments that come from a divine being. Among Buddhists, youre more likely to hear about skillful and unskillful means for minimizing suffering and maximizing the possibility for liberation.

The everybody ought language that wouldnt be the language theyd use, Evan Thompson, a University of British Columbia professor who specializes in Asian philosophical traditions, told me. The idea is that in order to lead a good life, we need to engage in certain self-cultivation practices, such as training our minds to calm down so we can pay attention to the present.

Plus, whereas the language of oughts and obligations suggests a prescriptive or proselytizing attitude, Buddhist tradition has generally been more interested in inviting people to try meditation and discover its benefits for themselves, rather than in mandating adherence. (Not all people who identify as Buddhist practice meditation.)

Jinpa said it would be naive to think someone could get everyone to meditate. That wont happen, he told me. So Im interested in promoting the idea of compassion training that wouldnt necessarily involve formal sitting meditation. He pointed to his Compassion Cultivation Training as an example, saying its likelier to be widely adopted in part because its presented as secular.

Meanwhile, to Davidson, the neuroscientist, the virtues you cultivate by meditating are so crucial as to make the practice feel almost obligatory.

I see this as a public health need, he told me, using the analogy of brushing our teeth something that takes only a few minutes a day, and something that virtually everyone does because we see it as important for our physical hygiene.

I think most people would agree their minds are just as important as their teeth. If we spent such a short time on our mind as we do on brushing our teeth, this world would be a different place, Davidson said, because our emotional well-being would be improved. So there is some sense of a moral obligation, almost.

But theres a caveat: For a small minority of people, meditation can actually provoke adverse effects, like intense mental distress or impaired physical functioning. Brown University psychologist Willoughby Britton is studying these cases in a project called Varieties of Contemplative Experience. More research is still needed, but given that meditation practices might precipitate or exacerbate challenging conditions in some people, it would be wrong to say that absolutely everyone would do well to meditate.

Scientists are publishing more and more studies on meditation each year. But many of these studies are beset by methodological flaws, leading to overhyped results. Davidson calls this neuromythology.

Some studies fail to replicate in other labs. Others fail to include active controls they dont test the potential benefits of a meditation regimen against those of a different regimen, like exercise or health education classes. Still others fail to disaggregate the data of participants who are relatively inexperienced with meditation and those whove had enough hours of practice to be considered experts.

Even though there are methodological issues with some of the studies, others do hold up. And when you consider the hundreds of studies altogether, there is substantial evidence that meditation can help us become better people.

So, the next question is: How much better? Is it worth spending hours on meditation when you could just get out there and start volunteering?

My response to that is, why pose it as an either/or question? I think both are important, Davidson said. Id say the biggest bang for your buck would be to engage in a compassion meditation practice in your mind while youre volunteering.

When we think about meditation, we often picture ourselves sitting on a cushion with our eyes closed. But it doesnt have to look that way. It can just be a state of mind with which we do whatever else it is were doing: volunteering, commuting to work, drinking a cup of tea, washing the dishes.

In fact, the Zen Buddhist monk Thich Nhat Hanh is fond of saying, Washing the dishes is like bathing a baby Buddha. The profane is the sacred. Everyday mind is Buddhas mind.

As for me, Ive found that I have enough bandwidth at the end of the day to sit down and close my eyes for a few minutes. So, for eight weeks, I sat in meditation every night.

Then I went home to visit my family.

Im happy to report that we had our best, calmest visit in years. By the end of the holiday break, the number of fights Id gotten into was a glorious, miraculous zero.

Its not that all of my reactive or unkind impulses magically disappeared. But whenever I felt myself starting to get snippy, I went into my old childhood bedroom and closed the door. I took a deep breath, and recalling the heaps of scientific evidence that had confronted me, I did what seemed to me like the reasonable response, a response so easy and so beneficial that it felt like a no-brainer.

Reader, I meditated.

Reporting for this article was supported by Public Theologies of Technology and Presence, a journalism and research initiative based at the Institute of Buddhist Studies and funded by the Henry Luce Foundation.

Sign up for the Future Perfect newsletter. Twice a week, youll get a roundup of ideas and solutions for tackling our biggest challenges: improving public health, decreasing human and animal suffering, easing catastrophic risks, and to put it simply getting better at doing good.

Future Perfect is funded in part by individual contributions, grants, and sponsorships. Learn more here.

Continue reading here:
Meditation can better the brain. Are we morally obligated to meditate? - Vox.com

Neuroscience Antibodies & Assays Market 2020 Analysis Focusing On Top Companies- Thermo Fisher Scientific, Tecan, Santa Cruz Biotechnology,…

New Jersey, United States, The report titled Neuroscience Antibodies & Assays Market is one of the most comprehensive and important additions to Verified Market Researchs archive of market research studies. It offers detailed research and analysis of key aspects of the Neuroscience Antibodies & Assays market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the Neuroscience Antibodies & Assays market. Market participants can use the analysis on market dynamics to plan effective growth strategies and prepare for future challenges beforehand. Each trend of the Neuroscience Antibodies & Assays market is carefully analyzed and researched about by the market analysts.

Neuroscience Antibodies & Assays Market was valued at USD 2.42 Billion in 2018 and is projected to reach USD 5.14 Billion by 2026, growing at a CAGR of 9.7% from 2019 to 2026.

Request a Sample Copy of this report @https://www.verifiedmarketresearch.com/download-sample/?rid=28342&utm_source=BTN&utm_medium=009

Top 10 Companies in the Global Neuroscience Antibodies & Assays Market Research Report:

Global Neuroscience Antibodies & Assays Market: Competitive Landscape

Competitive landscape of a market explains strategies incorporated by key players of the market. Key developments and shift in management in the recent years by players has been explained through company profiling. This helps readers to understand the trends that will accelerate the growth of market. It also includes investment strategies, marketing strategies, and product development plans adopted by major players of the market. The market forecast will help readers make better investments.

Global Neuroscience Antibodies & Assays Market: Segment Analysis

This section of the report includes segmentation such as application, product type, and end user. These segmentations aid in determining parts of market that will progress more than others. The segmentation analysis provides information about the key elements that are thriving the specific segments better than others. It helps readers to understand strategies to make sound investments. The Global Neuroscience Antibodies & Assays Market is segmented on the basis of product type, applications, and its end users.

Global Neuroscience Antibodies & Assays Market: Regional Analysis

This part of the report includes detailed information of the market in different regions. Each region offers different scope to the market as each region has different government policy and other factors. The regions included in the report are North America, South America, Europe, Asia Pacific, and the Middle East. Information about different region helps the reader to understand global market better.

Ask for Discount @https://www.verifiedmarketresearch.com/ask-for-discount/?rid=28342&utm_source=BTN&utm_medium=009

Table of Content

1 Introduction of Neuroscience Antibodies & Assays Market

1.1 Overview of the Market 1.2 Scope of Report 1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining 3.2 Validation 3.3 Primary Interviews 3.4 List of Data Sources

4 Neuroscience Antibodies & Assays Market Outlook

4.1 Overview 4.2 Market Dynamics 4.2.1 Drivers 4.2.2 Restraints 4.2.3 Opportunities 4.3 Porters Five Force Model 4.4 Value Chain Analysis

5 Neuroscience Antibodies & Assays Market, By Deployment Model

5.1 Overview

6 Neuroscience Antibodies & Assays Market, By Solution

6.1 Overview

7 Neuroscience Antibodies & Assays Market, By Vertical

7.1 Overview

8 Neuroscience Antibodies & Assays Market, By Geography

8.1 Overview 8.2 North America 8.2.1 U.S. 8.2.2 Canada 8.2.3 Mexico 8.3 Europe 8.3.1 Germany 8.3.2 U.K. 8.3.3 France 8.3.4 Rest of Europe 8.4 Asia Pacific 8.4.1 China 8.4.2 Japan 8.4.3 India 8.4.4 Rest of Asia Pacific 8.5 Rest of the World 8.5.1 Latin America 8.5.2 Middle East

9 Neuroscience Antibodies & Assays Market Competitive Landscape

9.1 Overview 9.2 Company Market Ranking 9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview 10.1.2 Financial Performance 10.1.3 Product Outlook 10.1.4 Key Developments

11 Appendix

11.1 Related Research

Request Customization of Report @ https://www.verifiedmarketresearch.com/product/Neuroscience-Antibodies-&-Assays-Market/?utm_source=BTN&utm_medium=009

Highlights of Report

About Us:

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Analysts with high expertise in data gathering and governance utilize industry techniques to collate and examine data at all stages. Our analysts are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research reports.

Contact Us:

Mr. Edwyne Fernandes Call: +1 (650) 781 4080 Email: [emailprotected]

Go here to read the rest:
Neuroscience Antibodies & Assays Market 2020 Analysis Focusing On Top Companies- Thermo Fisher Scientific, Tecan, Santa Cruz Biotechnology,...

ProMIS Neurosciences to present at Sachs 3rd Annual Neuroscience Innovation Forum – Benzinga

TORONTO and CAMBRIDGE, Mass., Jan. 09, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX:PMN) (OTCQB:ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced its participation in the Sachs 3rd Annual Neuroscience Innovation Forum being held on January 12, 2020 at the Marine's Memorial Club, San Francisco, CA.

ProMIS' President and CEO, Elliot Goldstein, MD will provide overviews of its novel drug discovery and development programs for Alzheimer's disease, Parkinson's disease and ALS(amyotrophic lateral sclerosis). The audio webcast and slides of Dr. Goldstein's presentation will be available approximately one week following the conference presentation on ProMIS' web site https://promisneurosciences.com.

About ProMIS NeurosciencesProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). The Company's proprietary target discovery platform is based on the use of two complementary thermodynamic, computational discovery engines ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique precision approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.

To learn more, visit us at http://www.promisneurosciences.com, follow us onTwitter and LinkedIn and listen to the podcast, Saving Minds, at iTunes or Spotify.

For media inquiries, please contact:Shanti Skiffingtonshanti.skiffington@gmail.comTel. 617 921-0808

For Investor Relations please contact:Alpine Equity AdvisorsNicholas Rigopulos, Presidentnick@alpineequityadv.comTel. 617 901-0785

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Read more here:
ProMIS Neurosciences to present at Sachs 3rd Annual Neuroscience Innovation Forum - Benzinga

Mahana Therapeutics Enters Into Licensing Agreement With King’s College London for Innovative Digital Therapeutic to Treat Gastrointestinal Condition…

SAN FRANCISCO and LONDON, Jan. 10, 2020 /PRNewswire/ -- Mahana Therapeutics, a digital therapeutics company reimagining the treatment of chronic diseases, today announced that the Company has entered into a licensing and collaboration agreement with King's College London, a leading research university and one of the oldest and most prestigious universities in England.Mahana has acquired a worldwide exclusive license to an innovative digital therapeutic for the treatment of irritable bowel syndrome (IBS).

Professor Rona Moss-Morris, Head of Psychology Department, Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King's College London led the development of the digital program in collaboration with Trudie Chalder, Professor of Cognitive Behavioural Psychotherapy and Dr. Alice Sibelli both also from King's, Hazel Everitt, GP and Professor of Primary Care Research, Faculty of Medicine, University of Southampton, and a broad multi-university team."We spent over 18 years developing and clinically testing a personalized digital CBT program for adult IBS patients," said Rona Moss Morris."We believe our multi-center, randomized controlled trial (RCT) of 558 patients is the largest clinical trial ever conducted demonstrating the clinical safety and efficacy of a digital CBT product for IBS."The trial, with results published in 2019 prestigious medical journal Gut[1],demonstrated that web-based CBT showed substantial and durable IBS symptom severity improvements versus treatment as usual (i.e. doctors visits alone) and also led to reductions in anxiety and depression in patients over three, six and twelve-month time periods.

"The digital era has allowed us the opportunity to explore new ways to reach patients and provide them with access to psychological-based therapies that help control symptoms in a more convenient way. We are thrilled to partner with Mahana Therapeutics. Mahana shares our vision to provide patients in the U.K. and abroad with clinically and cost-effective treatments for gastrointestinal diseases and they have been an amazing collaborative partner,"said Professor Moss-Morris.

"This is the perfect union of our vision at Mahana plus a leading academic institution's desire to bring world-leading research into the hands of patients,"said Robert Paull, co-founder and CEO of Mahana Therapeutics. "The digital therapeutic developed by Professor Moss-Morris and her colleagues at King's College London is best-in-class and supported by extensive clinical data. We are excited to bring this important treatment option to patients in the United Kingdom, United States and globally."

About Mahana Therapeutics

Mahana is focused on developing digital therapeutics for children and adults living with gastrointestinal diseases and conditions. The company is a diverse mix of healthcare and technology entrepreneurs, gastroenterologists, psychologists, behavioral scientists, and passionate patients looking to improve the health and quality of life of people living with chronic gastrointestinal conditions.Mahana is based in San Francisco, California and London, England and is backed by leading venture capital firms Lux Capital and JAZZ Venture Partners.For more information please visit http://www.mahanatx.comor email press@mahanatx.com.

About King's College London and the Institute of Psychiatry, Psychology & NeuroscienceKing's College London is one of the top 10 UK universities in the world (QS World University Rankings, 2018/19) and among the oldest in England. King's has more than 31,000 students (including more than 12,800 postgraduates) from some 150 countries worldwide, and some 8,500 staff.King's has an outstanding reputation for world-class teaching and cutting-edge research. In the 2014 Research Excellence Framework (REF), eighty-four per cent of research at King's was deemed 'world-leading' or 'internationally excellent' (3* and 4*).

The Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King's College London is the premier centre for mental health and related neurosciences research in Europe. It produces more highly cited publications in psychiatry and mental health than any other university in the world (Scopus, 2016), with 31 of the most highly cited scientists in this field. World-leading research from the IoPPN has made, and continues to make, an impact on how we understand, prevent and treat mental illness and other conditions that affect the brain. http://www.kcl.ac.uk/ioppn@KingsIoPPN

About University of Southampton

The University of Southampton drives original thinking, turns knowledge into action and impact, and creates solutions to the world's challenges. We are among the top 100 institutions globally (QS World University Rankings 2019). Our academics are leaders in their fields, forging links with high-profile international businesses and organisations, and inspiring a 24,000-strong community of exceptional students, from over 135 countries worldwide. Through our high-quality education, the University helps students on a journey of discovery to realize their potential and join our global network of over 200,000 alumni. http://www.southampton.ac.uk

[1] Everitt HA, et al. Gut 2019;0:111. doi:10.1136/gutjnl-2018-317805

Related Images

mahana-therapeutics-logo.jpg Mahana Therapeutics Logo

View original content to download multimedia:http://www.prnewswire.com/news-releases/mahana-therapeutics-enters-into-licensing-agreement-with-kings-college-london-for-innovative-digital-therapeutic-to-treat-gastrointestinal-condition-300985209.html

SOURCE Mahana Therapeutics

Originally posted here:
Mahana Therapeutics Enters Into Licensing Agreement With King's College London for Innovative Digital Therapeutic to Treat Gastrointestinal Condition...

Michael Egnor: How Experiments Show that the Mind Is More than the Brain – Discovery Institute

On a classic episode of ID the Future, host Ray Bohlin talks with Michael Egnor, a pediatric neurosurgeon and professor of neurosurgery at Stony Brook University, about ways modern science validates the idea that the mind is not reducible to the brain. They delve into oddities of neuroscience that indicate that there is more going on in the brain than mere chemistry, and, in particular, walk through the seminal work of Adrian Owen on MRIs and what they reveal. Download the podcast or listen to it here.

Photo: Michael Egnor at theinauguration of the Walter Bradley Center for Natural & Artificial Intelligence, by Nathan Jacobson.

See the article here:
Michael Egnor: How Experiments Show that the Mind Is More than the Brain - Discovery Institute

Brains Are Amazing Neuroscientists Discover L2/3 Human Neurons Can Compute the XOR Operation – Synced

When talk of artificial neural networks began some fifty years ago the idea was to mimic the behaviour and function of the neurons in human brains a premise that has more or less survived to this day. But new research now suggests scientists may have severely underestimated the power and potential of our neurons.

Brains are amazing. Our lab demonstrates that single human layer 2/3 neurons can compute the XOR operation. Never seen before in any neuron in any other species The tweet from Humboldt University of Berlin Research Fellow and Neuroscientist Jaan Aru introduced the paper Dendritic Action Potentials and Computation in Human Layer 2/3 Cortical Neurons to a surprised neuroscience research community. Recently published in Science, the paper authors are from Humboldt, Charit Universittsmedizin Berlin, and the Foundation for Research and Technology Hellas (FORTH).

The human brain has evolved an extraordinarily thick cortex with layers 2 and 3 (L2/3 of 6) particularly important in cognitive function. These L2/3 human cortical neurons form dendritic trees, which the researchers explain largely determine the repertoire of transformations of the synaptic inputs to axonal action potentials (APs) at the output. Thus, they constitute a key element of the neurons computational power.

Its believed one of the reasons these human brain neurons abilities remained undiscovered is because previous knowledge of active dendrites was developed almost entirely from studies on rodents.

In their investigation of the dendrites of L2/3 neurons the researchers discovered waveform and effects on neuronal output fromdCaAPs, a class of calcium-mediated dendritic action potentials: In contrast to typical all-or-none action potentials, dCaAPs were graded; their amplitudes were maximal for threshold-level stimuli but dampened for stronger stimuli. These dCaAPs enabled the dendrites of individual human neocortical pyramidal neurons to classify linearly nonseparable inputsa computation conventionally thought to require multilayered networks.

It had been assumed that tasks such as XOR could not be performed by a single neuron. In fact it takes a two-layer artificial neural network to compute XOR (Exclusive Or) a basic logical operationthat gives a true (1 or HIGH) output when the number of true inputs is odd.

The discoveries provide an exciting new perspective on how neurons work and how our brains process information. Says Oberlin College Neuroscience graduate Yujia Liu: If the findings can be further examined in more detail in terms of explainability and interpretability, there may be some insights for creating a new type of artificial neurons. Inspired by the research, an equally powerful artificial neural network could be created without so many neurons.

The paper Dendritic Action Potentials and Computation in Human Layer 2/3 Cortical Neurons is available on Science.

Journalist: Fangyu Cai | Editor: Michael Sarazen

Like Loading...

Excerpt from:
Brains Are Amazing Neuroscientists Discover L2/3 Human Neurons Can Compute the XOR Operation - Synced

BrainStorm Cell Therapeutics to Present at the 2020 Biotech Showcase and 3rd Annual Neuroscience Innovation Forum at JPM Week – Yahoo Finance

NEW YORK, Jan. 07, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Chaim Lebovits, President and Chief Executive Officer, will provide a corporate overview at the 2020 Biotech Showcase, being held on January 13-15, 2020 at the Hilton San Francisco Union Square in San Francisco, California.

Mr. Lebovits will also present at the 3rd Annual Neuroscience Innovation Forum, taking place on January 12, 2020, at the Marines Memorial Club in San Francisco. Additionally, Ralph Kern M.D., MHSc, BrainStorms Chief Operating Officer and Chief Medical Officer, will participate on aRare & Orphan Diseases Panel.

2020 Biotech Showcase

Details

Date:

Monday, January 13, 2020

Time:

11:00 am Pacific Time

Location:

Hilton San Francisco Union Square, Hilton/Yosemite A, Ballroom Level

Presenter:

Chaim Lebovits, CEO

Webcast:

https://bit.ly/37EfFfC

Rare & Orphan Disease Panel:

Details

Date:

Sunday, January 12, 2020

Time:

10:45 am Pacific Time

Location:

Marines Memorial Club, SF

Presenter:

Dr. Ralph Kern, COO & CMO

Meetings

BrainStorms senior management will also be hosting institutional investor and partnering meetings at the 2020 Biotech Showcase conference (https://goo.gl/SGFm62). Please use the Investor contact information provided below to schedule a meeting.

About NurOwn

NurOwn (autologous MSC-NTF cells) represent a promising investigational approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. NurOwn is currently being evaluated in a Phase 3 ALS randomized placebo-controlled trial and in a Phase 2 open-label multicenter trial in Progressive MS.

Story continues

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (U.S. FDA) and the European Medicines Agency (EMA) in ALS. BrainStorm has fully enrolled a Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six sites in the U.S., supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. For more information, visit BrainStorm's website at http://www.brainstorm-cell.com.

Safe-Harbor Statement

Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could causeBrainStorm Cell Therapeutics Inc.'sactual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorms need to raise additional capital, BrainStorms ability to continue as a going concern, regulatory approval of BrainStorms NurOwn treatment candidate, the success of BrainStorms product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorms NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorms ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorms ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CONTACTS

Corporate:Uri YablonkaChief Business OfficerBrainStorm Cell Therapeutics Inc.Phone: 646-666-3188uri@brainstorm-cell.com

Media:Sean LeousWestwicke/ICR PRPhone: +1.646.677.1839sean.leous@icrinc.com

Continue reading here:
BrainStorm Cell Therapeutics to Present at the 2020 Biotech Showcase and 3rd Annual Neuroscience Innovation Forum at JPM Week - Yahoo Finance

Harnessing biology and technology to develop much-needed treatments for depression – News-Medical.net

New research into the biology of depression, along with new and evolving technologies, provides the basis for developing the next generation of treatments for major depressive disorder (MDD), according to the special January/February issue of Harvard Review of Psychiatry. The journal is published in the Lippincott portfolio by Wolters Kluwer.

By embracing a multifactorial understanding of MDD, by attending carefully to the sex difference in its prevalence and manifestation, and by harnessing new technology, we should be increasingly able to prevent and treat depression."

Guest Editor Diego A. Pizzagalli, PhD, of McLean Hospital, Belmont, Mass.

Contributed by international experts, the five articles in the special issue provide updates on neuroscience and technology that may inform the development of much-needed treatments for depression. Topics include:

Gender Differences in Depression. After age 12, MDD is twice as common in girls compared to boys. Studies have yielded insights into the affective, biological, and cognitive factors contributing to this gender difference - for example, negative emotionality, pubertal hormones, and negative cognitive style. While each factor has a relatively small effect on risk, past and present stressors amplify their impact. Continued research may lead to evidence-based treatments that better take into account the particular needs and circumstances of girls and women.

Neuroscience and Behavioral Interventions. "Neuroscience-based augmentation strategies" are being pursued to address two key aspects of depression: anhedonia (loss of interest in pleasurable activities) and cognitive deficits/biases. An approach called Positive Affect Treatment targets issues related to motivation, reward attainment, and reward learning. In an initial clinical trial, this approach showed benefits including decreases in depression symptoms, suicidal thoughts, and stress.

Role of the Microbiome. Evidence suggests that the gut microbiome - the community of bacteria and other microbes living in the intestinal tract - may contribute to the development and persistence of MDD. The microbiome is altered in patients with depression, and commonly used antidepressant drugs affect the microbiome. For example, studies have suggested that a diet high in anti-inflammatory foods (such as the Mediterranean diet) may shorten episodes of depression.

Opioid-Based Therapies. Compelling evidence suggests that abnormal opioid signaling may play a role in the development of MDD. This may help to explain why many patients don't respond to current antidepressant medications. Opioid mechanisms might also account for rapid antidepressant responses to the anesthetic drug ketamine. Strategies targeting one or more of the four opioid receptor subtypes might open new approaches to treating MDD and other stress-related disorders.

Technology in Depression Treatment. Wearable devices, global positioning systems (GPS), and other technologies may provide valuable tools for understanding the wide variation in symptom and disease expression (phenotype) of MDD. For example, GPS devices or fitness trackers may provide useful information on symptoms of social isolation, physical inactivity, and sleep disruption. These and other approaches such as natural language processing and ecological momentary assessment could provide real-time assessment of depression's impact on the lives of individual patients.

While current evidence-based treatments, including antidepressant medications and psychotherapy, are helpful for many people, an "unacceptably high" proportion of patients with depression derive no benefit from these treatments. "There's an acute need for new understandings of depression and its impact on patients' lives," Dr. Pizzagalli comments. "We hope the insights provided by the special issue papers will help to spur the development of new and better treatment approaches that our patients urgently need."

Source:

Journal reference:

Pizzagalli, D. A. (2020) Special issue: Harnessing Biology and Technology to Develop New Depression Treatments. Harvard Review of Psychiatry. doi.org/10.1097/HRP.0000000000000244.

Read the rest here:
Harnessing biology and technology to develop much-needed treatments for depression - News-Medical.net

Watch: Why most parenting advice may be wrong – The Indian Express

By: Parenting Desk | Published: January 12, 2020 12:07:10 pm

From relatives, peers to books, everyone has a load of advice for parents to raise the perfect child. In a Ted Talk, professor of psychology and neuroscience Yuko Munakata spoke about how the parenting advice you receive can also turn out to be faulty.

The problem is that parenting books send conflicting messages. The one consistent message is that if your child is not succeeding, you are doing something wrong. Science supports a totally different message, she said.

Children can be shaped by many forces that are often intertwined like successful parents, successful genes, successful peers and a culture of success that they grow up in, the professor argued.

Everyone cant possibly be right about how parenting works, given how wildly beliefs have varied, said Munakata. The same style of parenting can impact children of the same parent in different ways. Your parenting can be shaping your children, just not in ways that would lead them to become more alike, she said.

Parents have influence but they do not have control, the professor emphasised.

For all the latest Parenting News, download Indian Express App

IE Online Media Services Pvt Ltd

Read more:
Watch: Why most parenting advice may be wrong - The Indian Express

Parker University Announces Clint Gilchrist as New CFO January 11, 2020Will Support Initiative to Expand – PR Web

Im honored to be at Parker University during this exciting time in our history. Im grateful to be able to play a part in continuing Dr. Parkers legacy and enhancing the educational experience for our students under the visionary leadership of President Morgan and the Board.

DALLAS (PRWEB) January 11, 2020

Parker University, the health and wellness college that is the 4th-fastest growing school in the state announced the hiring of Clint Gilchrist as its new CFO. Gilchrist, a CPA, was previously controller for Southern Methodist University. He will begin January 7.

Im honored to be at Parker University during this exciting time in our history. Im grateful to be able to play a part in continuing Dr. Parkers legacy and enhancing the educational experience for our students under the visionary leadership of President Morgan and the Board. he said.

The timing of the appointment couldnt be at a more crucial juncture. Parker University enrollment is at an all-time high. This past November, half its campus was destroyed in a freak tornado that blew through the area. This unfortunate event is now being used as a catalyst to raise funds to build a new outpatient chiropractic clinic, modernize research facilities, and enhance the student experience.

Its more important than ever that we have someone like Clint help us navigate these expansion years, said Parker President William E. Morgan. His experience in strategic financial operations for higher universities will serve us well.

The year 2020 marks both the 100th birthday of Dr. Parker and the 125th anniversary of the discovery of chiropractic. The school hopes to celebrate by showcasing a modern, rebuilt facility.With CFO Gilchrist at the helm, it seems highly likely they will be successful.

About Parker University

Parker University was founded in 1982 by Dr. James William Parker, originally as Parker College of Chiropractic; in 2011, it changed the name as its curriculum expanded. Today it is the 4th fastest growing college in Texas, according to the Dallas Business Journal. Parker University has 1,500 students and 27 academic programs including its famed chiropractic program along with masters degrees in neuroscience, clinical neuroscience, and functional nutrition. Currently, Parker Universitys chiropractic cohort is the second largest of any campus in the world.

Share article on social media or email:

The rest is here:
Parker University Announces Clint Gilchrist as New CFO January 11, 2020Will Support Initiative to Expand - PR Web